logo
  • Home
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls/Updates
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact
    • Social Media Community Guidelines

Press Releases

  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
    • 30 DEC 2013

    Dr. Mark L. Rabe Develops Charter for Scientific Advisory Board of Nuvilex’s Subsidiary, Medical Marijuana Sciences, Inc.

    SILVER SPRING, Md., Dec. 30, 2013 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Dr. Mark L. Rabe, Chairman of the Scientific Advisory Board (SAB) of its wholly-owned subsidiary Medical Marijuana Sciences, Inc., has developed a Charter and

    Read more →
    • Posted in
    • News
    • 19 DEC 2013

    Nuvilex’s Provides Progress Update on Cell Cloning Being Performed by Inno Biologics

    SILVER SPRING, Md., Dec. 19, 2013 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, provided an update today on the progress made by its contractor, Inno Biologics, regarding the cloning of the cancer-prodrug ifosfamide-activating cells that form the basis for the

    Read more →
    • Posted in
    • News
    • 12 DEC 2013

    Nuvilex’s Preparations for Planned Late-Phase Clinical Trials Timely in Light of Increasing Incidence of Pancreatic Cancer

    SILVER SPRING, Md., Dec. 12, 2013 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, commented today that ongoing preparations for its planned late-phase clinical trials appear to be timely as recent reports in the scientific literature point to an ever-increasing incidence

    Read more →
    • Posted in
    • News
    • 11 DEC 2013

    Nuvilex’s Contractor, Inno Biologics, Employs Clone-Pix(TM) Technology in Cloning Cells for Future Clinical Trials

    SILVER SPRING, Md., Dec. 11, 2013 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its contractor, Inno Biologics Sdn. Bhd., is using the Clone-Pix(TM)technology for the isolation and selection of clones preparatory to obtaining the large numbers of

    Read more →
    • Posted in
    • News
    • 09 DEC 2013

    Nuvilex Holds High Level Strategic Meetings to Solidify Company Objectives and Plans for Future Research and Development

    SILVER SPRING, Md., Dec. 9, 2013 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today it recently held three days of meetings to solidify the objectives and plans of PharmaCyte Biotech for future research and development. The participants included the

    Read more →
    • Posted in
    • News
    • 07 NOV 2013

    Nuvilex Completes Acquisition of Exclusive Worldwide Rights to Live-Cell Encapsulation Technology for Diabetes

    SILVER SPRING, Md., Nov. 7, 2013 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has acquired the exclusive worldwide rights to use the cellulose-based live-cell encapsulation technology for the development of treatments for diabetes from SG Austria

    Read more →
    • Posted in
    • News
    • 04 NOV 2013

    Nuvilex Announces Cloning of Cells for Future Phase 3 Clinical Trials Initiated by Inno Biologics

    SILVER SPRING, MD–(Marketwired – Nov 4, 2013) – PharmaCyte Biotech, Inc. (OTCQB: NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that cloning of the cancer-drug-activating cells required for PharmaCyte Biotech’s future Phase 3 clinical trials has begun at Inno Biologics in its cGMP-compliant facilities. Following

    Read more →
    • Posted in
    • News
    • 17 SEP 2013

    Nuvilex Contracts With Inno Biologics, an FDA-Compliant Provider, for Initial Generation of Cloned Cells for Future Phase 3 Clinical Trials

    SILVER SPRING, Md., Sept. 17, 2013 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX) (“Company”), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today it has contracted Inno Biologics Sdn. Bhd. to generate cell clones that are the basis of the Company’s future Phase 3 cancer clinical trials.

    Read more →
    • Posted in
    • News
    • 11 SEP 2013

    Nuvilex Eyes FDA Fast Track After ABRAXANE Approved for Pancreatic Cancer

    NEW YORK, NY–(Marketwired – Sep 11, 2013) – PharmaCyte Biotech, Inc. (OTCQB: NVLX) and its shareholders enjoyed what could be a dress rehearsal of their own future with the Food and Drug Administration’s (FDA) Fast Track program. Late last week Celgene announced that the FDA has approved its supplemental new drug application for ABRAXANE® when

    Read more →
    • Posted in
    • News
    • 10 SEP 2013

    Nuvilex Contracts Fisher BioServices, Inc. for Long-Term Storage of Cells for Future Phase 3 Clinical Trials

    SILVER SPRING, MD–(Marketwired – Sep 10, 2013) – PharmaCyte Biotech, Inc. (OTCQB: NVLX) (Company), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today it has contracted Fisher BioServices, Inc. for the long-term storage of cells that will be required for its future Phase 3 and other cancer

    Read more →
    • Posted in
    • News
  • 1
  • 2